HELIX BIOPHARMA CORP (HBP.CA) Stock Fundamental Analysis

Canada • Toronto Stock Exchange • TSX:HBP • CA4229102088

1.89 CAD
-0.14 (-6.9%)
Last: Feb 2, 2026, 07:00 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to HBP. HBP was compared to 23 industry peers in the Biotechnology industry. HBP has a bad profitability rating. Also its financial health evaluation is rather negative. HBP does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year HBP has reported negative net income.
  • HBP had a negative operating cash flow in the past year.
  • In the past 5 years HBP always reported negative net income.
  • In the past 5 years HBP always reported negative operating cash flow.
HBP.CA Yearly Net Income VS EBIT VS OCF VS FCFHBP.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2M -4M -6M -8M -10M

1.2 Ratios

  • The Return On Assets of HBP (-25.58%) is better than 69.57% of its industry peers.
  • HBP's Return On Equity of -30.36% is fine compared to the rest of the industry. HBP outperforms 73.91% of its industry peers.
Industry RankSector Rank
ROA -25.58%
ROE -30.36%
ROIC N/A
ROA(3y)-420.37%
ROA(5y)-326.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HBP.CA Yearly ROA, ROE, ROICHBP.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20K 40K 60K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for HBP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HBP.CA Yearly Profit, Operating, Gross MarginsHBP.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

3

2. Health

2.1 Basic Checks

  • The number of shares outstanding for HBP has been increased compared to 1 year ago.
  • Compared to 5 years ago, HBP has less shares outstanding
  • Compared to 1 year ago, HBP has a worse debt to assets ratio.
HBP.CA Yearly Shares OutstandingHBP.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
HBP.CA Yearly Total Debt VS Total AssetsHBP.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M

2.2 Solvency

  • HBP has an Altman-Z score of 12.27. This indicates that HBP is financially healthy and has little risk of bankruptcy at the moment.
  • HBP has a Altman-Z score of 12.27. This is amongst the best in the industry. HBP outperforms 95.65% of its industry peers.
  • HBP has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of HBP (0.02) is better than 78.26% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 12.27
ROIC/WACCN/A
WACCN/A
HBP.CA Yearly LT Debt VS Equity VS FCFHBP.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M 10M -10M 15M

2.3 Liquidity

  • HBP has a Current Ratio of 0.23. This is a bad value and indicates that HBP is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Current ratio of HBP (0.23) is worse than 60.87% of its industry peers.
  • A Quick Ratio of 0.23 indicates that HBP may have some problems paying its short term obligations.
  • HBP's Quick ratio of 0.23 is on the low side compared to the rest of the industry. HBP is outperformed by 60.87% of its industry peers.
Industry RankSector Rank
Current Ratio 0.23
Quick Ratio 0.23
HBP.CA Yearly Current Assets VS Current LiabilitesHBP.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M

More info and screens

0

3. Growth

3.1 Past

  • HBP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.84%, which is quite impressive.
EPS 1Y (TTM)56.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.28%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HBP.CA Yearly EPS VS EstimatesHBP.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 -0.1 -0.2 -0.3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • HBP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HBP.CA Price Earnings VS Forward Price EarningsHBP.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HBP.CA Per share dataHBP.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 -0.05 0.1 0.15 0.2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • HBP does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

HELIX BIOPHARMA CORP

TSX:HBP (2/2/2026, 7:00:00 PM)

1.89

-0.14 (-6.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)12-12
Earnings (Next)03-12
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners7.71%
Ins Owner ChangeN/A
Market Cap144.36M
Revenue(TTM)N/A
Net Income(TTM)-4.88M
Analysts80
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 8.99
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.08
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0
BVpS0.21
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -25.58%
ROE -30.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-420.37%
ROA(5y)-326.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.23
Quick Ratio 0.23
Altman-Z 12.27
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)65.64%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.28%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y50.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y29.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y29.75%
OCF growth 3YN/A
OCF growth 5YN/A

HELIX BIOPHARMA CORP / HBP.CA FAQ

What is the ChartMill fundamental rating of HELIX BIOPHARMA CORP (HBP.CA) stock?

ChartMill assigns a fundamental rating of 1 / 10 to HBP.CA.


What is the valuation status for HBP stock?

ChartMill assigns a valuation rating of 0 / 10 to HELIX BIOPHARMA CORP (HBP.CA). This can be considered as Overvalued.


What is the profitability of HBP stock?

HELIX BIOPHARMA CORP (HBP.CA) has a profitability rating of 1 / 10.


Can you provide the financial health for HBP stock?

The financial health rating of HELIX BIOPHARMA CORP (HBP.CA) is 3 / 10.